Skopos Labs, Inc. Phathom Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 3,456 shares of PHAT stock, worth $14,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,456Holding current value
$14,065% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$41.1 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$30.4 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$28.7 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$14.9 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$14.2 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $159M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...